Resveratrol attenuates moxifloxacin-induced oxidative damage in the liver, kidneys, brain, and serum of Wistar rats

Objective: Moxifloxacin, a widely used fluoroquinolone, has been associated with oxidative stress and tissue injury. Resveratrol may attenuate oxidative damage. This study investigated the effects of resveratrol co-administration on oxidative and apoptotic biomarkers in rats exposed to moxifloxacin. Methods: Twenty-four male Wistar albino rats were randomly assigned to three groups (n = 8 per group): (a) control; (b) moxifloxacin; and (c) moxifloxacin + resveratrol groups. Moxifloxacin was administered intraperitoneally at 50 mg/kg/day during the final 7 days of a 28-day experimental period, whereas resveratrol was administered at 40 mg/kg/day for 28 days. Levels of superoxide dismutase, malondialdehyde, and caspase-3 as well as total antioxidant status and total oxidant status were assessed in the serum, brain, kidney, and liver tissues. Results: Serum total antioxidant status significantly decreased in the moxifloxacin group compared with that in the control group (2.639 ± 0.169 vs. 3.531 ± 0.176 mmol Trolox equivalent/L, p = 0.007). Co-administration of moxifloxacin and resveratrol significantly increased serum total antioxidant status compared with administration of moxifloxacin alone (3.380 ± 0.190 vs. 2.639 ± 0.169 mmol Trolox equivalent/L, p = 0.018), whereas no significant difference was observed in the control group (p = 0.557). Kidney total oxidant status was significantly higher in the moxifloxacin group than in the control (p = 0.008) and moxifloxacin + resveratrol (p = 0.002) groups. Liver superoxide dismutase levels were significantly lower in the moxifloxacin group than in the control (p < 0.001) and moxifloxacin + resveratrol (p = 0.001) groups. Kidney caspase-3 levels were significantly increased in the moxifloxacin group compared with those in the control group (p < 0.001), whereas co-administration of moxifloxacin and resveratrol partially attenuated this alteration. Additionally, moxifloxacin increased the levels of malondialdehyde in the kidney, liver, and brain tissues, with attenuation following resveratrol co-administration. Conclusions: Resveratrol co-administration attenuated several moxifloxacin-associated oxidative and apoptotic alterations, particularly in the kidney and liver tissues. However, the absence of a resveratrol-only group and the preconditioning design limit the interpretation of its independent effects and clinical applicability. Further pharmacokinetic, mechanistic, and clinical studies are required.